Diabetes is the leading cause of chronic kidney disease and end-stage kidney disease worldwide.1 Many patients with diabetic kidney disease (DKD) die of a cardiovascular event before the initiation of kidney replacement therapy.2 In clinical trials, control of blood pressure (BP),3 blood glucose,4 and blood cholesterol level5 as well as use of renin-angiotensin-aldosterone system (RAAS) inhibitors,6 sodium-glucose cotransporter 2 inhibitors,7,8 and finerenone9 have been shown to improve cardiovascular and kidney outcomes and survival in patients with DKD. This evidence concerns the gene SLC5A2 and diabetic kidney disease.